Soleno Therapeutics Hit With Class Action Over VYKAT Launch Failures and Safety Disclosures

Soleno Therapeutics ($SLNO) is facing a securities class action lawsuit alleging the company misled investors about the safety profile and commercial viability of VYKAT™ XR (DCCR), its first-in-class treatment for hyperphagia. The litigation, brought by Hagens Berman, comes amid a devastating stock collapse and management's belated admission of serious launch disruptions that included far fewer prescription starts than anticipated and sharply elevated patient discontinuation rates. The legal action highlights the perils of unproven drug commercialization and raises critical questions about disclosure practices at smaller biotech firms navigating the complexities of rare disease markets.

The Crisis Unfolds: From Launch Promise to Legal Reckoning

The trouble began in August 2025 when a short seller report raised alarm bells about undisclosed safety concerns surrounding VYKAT XR, specifically flagging risks of fluid retention and hospitalizations that the company had not adequately communicated to investors. The allegations struck at the heart of the drug's clinical narrative and market potential, triggering immediate investor concern.

The market's response was swift and severe. $SLNO stock plummeted approximately 40% by November 2025, erasing substantial shareholder value in a matter of months. This dramatic decline reflected not only the initial safety allegations but also management's subsequent admission that the VYKAT XR launch was experiencing material headwinds:

• Lower-than-expected prescription starts in early commercial channels
• Significantly elevated patient discontinuation rates once treatment began
• Broader launch disruptions that undermined the company's previous guidance and investor expectations

These admissions suggested that either the company had minimized launch risks in prior communications or lacked adequate visibility into early commercialization dynamics. For investors who had anticipated steady revenue ramps following FDA approval, the revelations represented a fundamental repricing of the asset's near-term and medium-term value.

The Hagens Berman class action alleges that Soleno Therapeutics made materially misleading statements and omissions regarding the safety and commercial viability of the drug, potentially violating securities laws. The lawsuit suggests that management knew or should have known about safety concerns and commercial challenges but failed to disclose them in a timely manner to shareholders.

Market Context: Hyperphagia Drug Market and Competitive Pressures

Hyperphagia—excessive hunger and appetite dysregulation—represents a genuine unmet medical need, particularly in rare genetic disorders such as Prader-Willi syndrome. VYKAT XR was positioned as a first-in-class solution to this problem, offering Soleno a potentially significant market opportunity with limited direct competition. The rarity of the condition and the scarcity of approved treatments meant that any successful launch could command premium pricing and generate outsized returns on development investment.

However, rare disease commercialization carries inherent challenges:

• Small patient populations require highly efficient identification and enrollment strategies
• Specialized distribution networks are often necessary, limiting traditional pharmacy channels
• Payer reticence toward unproven therapies and their cost-effectiveness profiles
• Safety and tolerability thresholds are particularly stringent in rare patient populations who may lack alternative options

The hyperphagia market, while niche, has attracted interest from larger biopharmaceutical companies and venture-backed startups alike. Any perception of safety issues or commercial struggles can rapidly erode confidence in the category itself, particularly when investor memory of previous failed launches in orphan indications remains fresh. Soleno's struggles may have ripple effects across perception of rare disease development generally.

The company's failure to successfully navigate the critical early launch phase—when establishing prescriber relationships, patient awareness, and consistent utilization patterns are paramount—suggests potential gaps in commercial execution, market education, or clinical support infrastructure.

Investor Implications: Valuation Reset and Corporate Governance Questions

The combination of safety concerns, commercial missteps, and litigation creates a severe headwind for $SLNO shareholders. Beyond the immediate stock price destruction, several longer-term risks emerge:

Valuation and Revenue Trajectory: The 40% stock decline reflects the market's dramatic repricing of VYKAT XR revenue potential. If discontinuation rates remain elevated and prescription starts persistently underperform, the drug's peak sales assumptions—likely the primary driver of pre-launch company valuations—may require substantial downward revision. This has immediate implications for the company's overall enterprise value and cash runway.

Regulatory and Commercial Momentum: Early-stage launch performance often determines physician and payer perception for years. If prescribers and payers view VYKAT XR as problematic or commercially oversold, correcting this narrative becomes exponentially harder. The company may face pricing pressure from payers citing safety concerns and low uptake as justification for restricted formulary status or reimbursement limitations.

Cash Burn and Financing Risk: Smaller biotech firms like Soleno typically operate with finite cash reserves. A collapsed stock price limits the company's ability to raise capital through equity issuance, potentially forcing dilutive financing or asset sales. Management must balance ongoing VYKAT XR commercialization efforts against the need to preserve cash and maintain financial flexibility.

Disclosure and Governance: The class action lawsuit raises questions about whether Soleno's disclosure controls and procedures were adequate. Did the company have real-time visibility into prescription and discontinuation metrics? Were safety signals being properly monitored and escalated? Regulatory investigations by the SEC or FDA could follow, further complicating the corporate environment.

Investors holding $SLNO shares face not only the direct financial loss but also the extended uncertainty of litigation resolution. Settlement or judgment could impose additional financial burdens or consent decrees affecting future disclosures and management practices.

Looking Forward: Path to Recovery Remains Uncertain

Soleno Therapeutics faces a critical inflection point. The company must simultaneously address the commercial challenges underlying VYKAT XR launch failures, establish comprehensive safety monitoring and communication protocols, and navigate litigation that could stretch across multiple years. Management's credibility with investors, prescribers, and payers has been materially damaged.

The path forward likely depends on several factors: whether safety concerns can be characterized as manageable through enhanced patient selection or monitoring protocols; whether prescription starts and discontinuation rates stabilize or reverse through improved market access and patient education; whether the litigation resolves quickly or drags on; and whether the company can maintain sufficient financial resources to sustain operations and commercialization efforts.

For investors, the $SLNO situation underscores the risk inherent in early-stage biotech equities, particularly those betting on rare disease launches. Execution risk is substantial, disclosure gaps can prove costly, and a single adverse event or failed commercial launch can destroy shareholder value rapidly. The coming months will determine whether this represents a temporary setback from which Soleno can recover, or a fundamental failure that portends a much longer period of underperformance and potential delisting risk.